Area of research
Cancer Research · Radiation
Research interest
Research focused on Breast cancer and Radiation therapy, with related work in Oncology, Tamoxifen, XRCC1. Notable publications include 'Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic...', 'REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer', and 'First results of the preoperative accelerated partial breast irradiation (PAPBI) trial'.
Integrating genetic polymorphisms and clinical data to develop predictive models for skin toxicity in breast cancer radiation therapy
Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer
Comparison of prone and supine positioning for breast cancer radiotherapy using REQUITE data: dosimetry, acute and two years physician and patient-reported outcomes
Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort
Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial
REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer
Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology
Preoperative radiotherapy in breast cancer patients: 32 years of follow-up
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience
First results of the preoperative accelerated partial breast irradiation (PAPBI) trial
XRCC1 Polymorphism Associated With Late Toxicity After Radiation Therapy in Breast Cancer Patients
Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study